Tnf Pharmaceuticals shifts from drug development to blockchain and computing. Key 2025 annual report on April 10, 2026, will detail strategic progress and capital allocation.
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Please provide your email address to receive an email when new articles are posted on . Patients treated with TNF inhibitors had respiratory hospitalization and mortality rates similar to patients on ...
Tumor necrosis factor (TNF) inhibitors protect patients with axial spondyloarthritis (axSpA) from hip and spine fractures better than other drugs. Large US insurance claims database study comparing ...
Please provide your email address to receive an email when new articles are posted on . TNF inhibitors within 3 years of diagnosis had no statistically significant negative link with colorectal, lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results